Armenija - engleski - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

excella gmbh & co.kg - chlorambucil - tablets film-coated - 2mg

Egipat - engleski - EDA (Egyptian Drug Authority)

egyptian pharmaceutical trading company - tablet - 5 mg

Saudijska Arabija - engleski - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

glaxowellcome, united kingdom - chlorambucil - film-coated tablet - 5 mg

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

aspen global inc. - chlorambucil (unii: 18d0sl7309) (chlorambucil - unii:18d0sl7309) - chlorambucil 2 mg - leukeran (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and hodgkin’s disease. it is not curative in any of these disorders but may produce clinically useful palliation. chlorambucil should not be used in patients whose disease has demonstrated a prior resistance to the agent. patients who have demonstrated hypersensitivity to chlorambucil should not be given the drug. there may be cross-hypersensitivity (skin rash) between chlorambucil and other alkylating agents.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

woodward pharma services llc - chlorambucil (unii: 18d0sl7309) (chlorambucil - unii:18d0sl7309) - leukeran (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and hodgkin’s disease. it is not curative in any of these disorders but may produce clinically useful palliation. chlorambucil should not be used in patients whose disease has demonstrated a prior resistance to the agent. patients who have demonstrated hypersensitivity to chlorambucil should not be given the drug. there may be cross-hypersensitivity (skin rash) between chlorambucil and other alkylating agents.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

waylis therapeutics llc - chlorambucil (unii: 18d0sl7309) (chlorambucil - unii:18d0sl7309) - leukeran (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and hodgkin’s disease. it is not curative in any of these disorders but may produce clinically useful palliation. chlorambucil should not be used in patients whose disease has demonstrated a prior resistance to the agent. patients who have demonstrated hypersensitivity to chlorambucil should not be given the drug. there may be cross-hypersensitivity (skin rash) between chlorambucil and other alkylating agents.

Armenija - engleski - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

excella gmbh & co.kg - chlorambucil - tablets film-coated - 2mg

Kanada - engleski - Health Canada

aspen pharmacare canada inc. - chlorambucil - tablet - 2mg - chlorambucil 2mg - antineoplastic agents

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - chlorambucil - oral tablet - 2mg

Malezija - engleski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

aspen medical products malaysia sdn bhd - chlorambucil -